REVIEW article
Front. Mol. Neurosci.
Sec. Molecular Signalling and Pathways
Volume 18 - 2025 | doi: 10.3389/fnmol.2025.1492807
Current Advances on RIPK2 and Its Inhibitors in Pathological Processes: A Comprehensive Review
Provisionally accepted
- 1Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
- 2Sir Run Run Hospital, Nanjing Medical University, Nanjing, Liaoning Province, China
- 3Jinhua Central Hospital, Jinhua, Zhejiang Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Receptor-Interacting Protein Kinase 2 (RIPK2) is a critical component of the signaling pathways downstream of Nucleotide-binding oligomerization domain-like receptor (NOD-like receptor), playing a vital role in the immune response, particularly in the context of cellular transport, adaptive immunity, and tumorigenesis. Recent advances have further clarified the complex roles of RIPK2, offering insights into its structural and functional characteristics. In this review, we provide a comprehensive overview of RIPK2's involvement in signaling, examine the development of RIPK2 inhibitors, and discuss novel strategies for targeting RIPK2 in therapeutic applications.Additionally, we highlight the dynamic interactions between RIPK2 and NOD-like receptors and explore future directions for improving RIPK2-targeted therapies.
Keywords: RIPK2, nod-like receptors, protein structure, RIPK2 inhibitors, Ubiquitin signaling
Received: 11 Sep 2024; Accepted: 22 Apr 2025.
Copyright: © 2025 Yanan, Chen, Tao and shanshan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ling Tao, Jinhua Central Hospital, Jinhua, Zhejiang Province, China
Shen shanshan, Jinhua Central Hospital, Jinhua, Zhejiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.